Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention

Table 4

The association between thrombocytopenia and the occurrence of in-hospital outcomes in the ACS cohort ().

	ACS cohort ()
Clinical outcomes	With TCP ()	Without TCP ()	value	Adjusted odds ratio (95% CI)^$	value
	(%)
Primary outcome: all-cause mortality, bleeding, or transfusion	27 (5.4)	143 (3.1)	0.007	1.33 (0.82–2.16)	0.25
All-cause mortality	13 (2.6)	59 (1.3)	0.017	1.44 (0.71–2.93)	0.31
Bleeding	12 (2.4)	55 (1.2)	0.024	1.71 (0.88–1.71)	0.12
	11 (2.2)	31 (0.7)	0.001	2.56 (1.24–5.44)	0.011
Transfusion	13 (2.6)	62 (1.4)	0.027	1.44 (0.74–2.82)	0.28
RBC transfusion	13 (2.6)	53 (1.6)	0.006	1.74 (0.88–3.44)	0.11
Platelet transfusion	1 (0.2)	2 (0)	0.69
Plasma transfusion	3 (0.6)	11 (0.2)	0.31
Secondary outcome: MACE or CVA	19 (3.8)	123 (2.7)	0.14	1.10 (0.65–1.86)	0.73
MACE	15 (3.0)	75 (1.6)	0.027	1.34 (0.71–2.53)	0.36
Cardiac mortality	11 (2.2)	55 (1.2)	0.058	1.37 (0.65–2.90)	0.41
Myocardial infarction	3 (0.6)	18 (0.4)	0.74
Target vessel revascularization	1 (0.2)	2 (0)	0.69
Stent thrombosis	0 (0)	4 (0.1)	1.0
Ischemic CVA	4 (0.8)	53 (1.2)	0.63
Hemorrhagic CVA	0 (0)	1 (0)	1.0
Length of stay (days)	5 (3–7)	4 (3–7)	0.017	0.01 (-0.01–0.02)^&	0.56

ACS: acute coronary syndrome; TCP: thrombocytopenia; CI: confidence interval; MACE: major adverse cardiovascular events, including in-hospital cardiac mortality, myocardial infarction, target vessel revascularization, or stent thrombosis; CVA: cerebrovascular accident; BARC: Bleeding Academic Research Consortium; RBC: red blood cell. ^$Adjusted for the propensity score in regression models. ^& coefficient (95% CI) of lg10-transformed length of stay.